ClinicalTrials.gg
Status unknownNCT03794440Updated Jan 22, 2021

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

A Phase 2/3 interventional study of Sintilimab and IBI305 in Hepatocellular Carcinoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-22.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2020), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
595
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,310 studies in Carcinoma, Hepatocellular with a site in China — 486 open to participants now, 558 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Enrollment
56th of 1,034
595 · median 78
Started
2019
with 109 others
Phase 2/3
34 of 1,310
12 open now
Registered
376th of 1,310
by date

Among the 1,310 studies in Carcinoma, Hepatocellular with a site in China, this one is the 56th largest by enrollment of the 1,034 interventional ones that give a count, is one of 110 that started in 2019, is one of 34 in phase 2/3, and was the 376th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

486 of the 1,310 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

481 more — sign in →

All 486 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,310 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety, tolerability and effectiveness of Sintilimab in combination with IBI305 in patients with HCC as the first-line treatment compared with Sorafenib. This study is a randomised, Open-label,Multi-center Study. The primary endpoint is overall survival.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hepatocellular carcinoma confirmed by histology/cytology. Cirrhosis meets the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Diagnosis of Liver Diseases (AASLD).
  2. performance status between 0 and 1
  3. No systematic anti-tumor treatment has been performed.(End of postoperative chemotherapy for more than 6 months allowed).
  4. Barcelona Clinic Liver Cancer stage C. BCLC stage B, not suitable for radical surgery and/or local treatment.
  5. At least 1 lesion with at baseline by V1.1.
  6. : \<=7
  7. Adequate organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  1. With fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma components in tumor tissues.
  2. Have a history of hepatic encephalopathy or have a history of liver transplantation.
  3. With clinical symptoms requires drainage of pleural effusion, ascites or pericardial effusion.
  4. Central nervous system (CNS) .
  5. Uncontrolled high blood pressure, systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg after optimal medical treatment.
  6. Local treatment for liver lesions within 4 weeks.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
595 participants (actual)

Study arms

  • Experimental
    Sintilimab +IBI305

    Drug: Sintilimab · Drug: IBI305

  • Active comparator
    Sorafenib

    Drug: Sorafenib

Interventions

  • 200mg IV d1, Q3W

    Also known as: IBI308

  • DrugIBI305

    15mg/kg IV d1, Q3W

    Also known as: anti-VEGF monoclonal antibody

  • 400mg PO BID

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Time frame: up to 24 months after randomization

  2. Progression-free survival (PFS)

    Progression-free survival (PFS) in two arms based on RECIST V1.1 by Independent Radiological Review Committee, IRRC.

    Time frame: up to 24 months after randomization

Secondary outcomes

  1. PFS

    PFS in two arms based on RECIST V1.1 by investigator.

    Time frame: up to 24 months after randomization

  2. Objective response rate (ORR)

    Objective response rate (ORR) in two arms based on RECIST V1.1 by IRRC and investigator .

    Time frame: up to 24 months after randomization

  3. Disease control rate (DCR)

    DCR in two arms based on RECIST V1.1 by IRRC and investigator.

    Time frame: up to 24 months after randomization

  4. Duration of response (DOR)

    DOR in two arms based on RECIST V1.1 by IRRC and investigator.

    Time frame: up to 24 months after randomization

  5. Time to progression (TTP)

    TTP in two arms based on RECIST V1.1 by IRRC and investigator.

    Time frame: One assessment was performed every 6 weeks (±7 days) from the time of randomization, and once every 12 weeks (±7 days) after 48 weeks.

  6. Time to response (TTR)

    TTR in two arms based on RECIST V1.1 by IRRC and investigator.

    Time frame: up to 24 months after randomization

  7. PFS

    PFS in two arms based on mRECIST by IRRC.

    Time frame: up to 24 months after randomization

  8. Objective response rate (ORR)

    Objective response rate (ORR) in two arms based on mRECIST by IRRC.

    Time frame: up to 24 months after randomization

  9. Time to progression (TTP)

    TTP in two arms based on mRECIST by IRRC.

    Time frame: up to 24 months after randomization

  10. Duration of response (DOR)

    DOR in two arms based on mRECIST by IRRC.

    Time frame: up to 24 months after randomization

  11. Disease control rate (DCR)

    DCR in two arms based on mRECIST by IRRC.

    Time frame: up to 24 months after randomization

  12. Time to response (TTR)

    TTR in two arms based on mRECIST by IRRC.

    Time frame: up to 24 months after randomization

  13. Anti-drug antibody (ADA)

    Immunogenicity measured by anti-drug antibody (ADA) for Sintilimab and IBI305.

    Time frame: up to 24 months after randomization

  14. EORTC QLQ-C30

    Time frame: up to 24 months after randomization

  15. EORTC QLQ-HCC18

    Time frame: up to 24 months after randomization

07

Study locations

1 site
  • Hospital of Fudan University
    Shanghai, Shanghai 200032, China
08

References and documents

Publications

  • Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15. Erratum In: Lancet Oncol. 2021 Aug;22(8):e347. doi: 10.1016/S1470-2045(21)00386-7. PubMed 34143971 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2019 (actual). Primary completion is estimated for Dec 2022, 46 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2019
First posted
Jan 7, 2019
StartActual
Feb 11, 2019
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2022
Last update
Jan 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03794440
Responsible party
Sponsor
First posted
Jan 7, 2019
Start date
Feb 11, 2019
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Jan 22, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI305

Start the discussion